Nebraska voters approved medical cannabis, but patients still do not have a working state-licensed medical market. Nebraska Voters Are Moving Faster Than the Weed Law explains how Measure 437 created paper protection, Measure 438 ordered a regulated market, and new UNL data shows more residents reporting use of marijuana purchased legally outside Nebraska.
Kentucky’s Hospital Cannabis Problem
Kentucky’s Hospital Cannabis Problem exposes the gap between medical cannabis approval and bedside access. Kentucky now recognizes terminal illness in its program. However, hospitals, hospices, nursing homes, and other care settings may still decide whether patients can use cannabis where pain, fear, and end-of-life care are happening.
Idaho’s Cannabis Ballot Trap
Idaho’s Cannabis Ballot Trap explains how the Idaho Medical Cannabis Act failed to qualify for the November ballot, while HJR 4 gives voters a different cannabis question: whether the Legislature should control future marijuana legalization power. The issue is not only medical cannabis. It is whether voters keep the power to ask.
France Still Fears Legal Weed
France keeps extending medical cannabis access while politically resisting broader legalization. Pot Culture Magazine examines the country’s cautious framework, frozen patient access, regulatory delays, and the growing contradiction between public rhetoric and the reality of cannabis reform already unfolding inside France.
Louisiana Rebuilds the Weed War
Louisiana says HB 568 protects schools. Critics see something older beneath the language: another expansion of marijuana enforcement through invisible school-zone boundaries. As lawmakers rebuild cannabis penalties around geography and fear, the state’s long relationship with punishment politics comes roaring back into view.
Britain’s Legal Weed Lockout
The United Kingdom legalized medical cannabis in 2018, but most patients still cannot access it through the NHS. Private clinics filled the gap, creating a two-tier system where legal medicine exists, but access depends on money, specialist approval, narrow guidance, and a regulatory structure now facing sharper scrutiny.